Shares of Praxis Precision Medicines, Inc. (PRAX) jumped over 26% on Tuesday morning after the company reported positive results from a phase 2 study of epilepsy treatment.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline…
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.